A Randomized, Double-Blind, Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of FLX-787-ODT for Treatment of Muscle Cramps in Adult Subjects With Motor Neuron Disease
Phase of Trial: Phase II
Latest Information Update: 11 Aug 2017
At a glance
- Drugs FLX 787 (Primary)
- Indications Cramp
- Focus Therapeutic Use
- Acronyms COMMEND
- Sponsors Flex Pharma
- 02 Aug 2017 According to a Flex Pharma media release, company expects to report topline results from this study in the middle of 2018.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting according to a Flex Pharma media release.
- 31 Jul 2017 According to a Flex Pharma media release, company is on track to initiate the trial this quarter and data readouts expected in 2018.